Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Inclusion Criteria: * Locally advanced or metastatic NSCLC (IIIB-IV) * Failure of first line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) in advanced disease or subsequent relapse of disease following first line therapy * Man or woman 21 years and above * Adequate performance status (ECOG 0, and 1) * Patient must have adequate organ function * Written informed consent * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. Exclusion Criteria: * Any treatment with investigational agent within 10 days prior to registration for protocol therapy. * Cerebrovascular accident, transient ischemic attack or myocardial infarction within 3 months prior to registration for protocol therapy. * Evidence of pulmonary embolism within 3 months prior to registration for protocol therapy. * Any history of hematologic malignancies. * Patient with known positive HIV serology at screening. * Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study. * Uncontrolled hypertension (\>160/100 mm Hg despite optimal medical therapy). * Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 grade 2. * Patients in whom radiation or surgery is indicated * Significant swallowing disorders. * Small bowel surgery. * Suspicion of absorption disruption as a result of abdominal radiation * Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption. * Evidence of concurrent (\< 5 years) second malignancy * Mental disorders. * Inability to give written informed consent.